Evidence map›Paper›PMID 31615575›Full record

ArticleReproductive biology and endocrinology : RB&E2019

Amniotic fluid antiphospholipid antibodies: potential role in antiphospholipid syndrome-independent aberrant implantation process.

Valentina Bruno, Marzia Nuccetelli, Carlo Ticconi, Antonella Bruno, Federica Martelli, Maria Vittoria Capogna, Sergio Bernardini, Emilio Piccione, Adalgisa Pietropolli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Valentina BrunoAcademic Department of Biomedicine and Prevention, Section of Gynecology, University of Rome "Tor Vergata", Rome, Italy. valentinabruno_86@hotmail.it.ORCID http://orcid.org/0000-0002-0008-9573
Marzia NuccetelliDepartment of Experimental Medicine and Surgery, Tor Vergata University Hospital, Tor Vergata University, Rome, Italy.
Carlo TicconiAcademic Department of Surgical Sciences, Section of Gynecology, Tor Vergata University Hospital, University of Rome "Tor Vergata", 00133, Rome, Italy.
Antonella BrunoAcademic Department of Surgical Sciences, Section of Gynecology, Tor Vergata University Hospital, University of Rome "Tor Vergata", 00133, Rome, Italy.
Federica MartelliAcademic Department of Biomedicine and Prevention, Section of Gynecology, University of Rome "Tor Vergata", Rome, Italy.
Maria Vittoria CapognaAcademic Department of Surgical Sciences, Section of Gynecology, Tor Vergata University Hospital, University of Rome "Tor Vergata", 00133, Rome, Italy.
Sergio BernardiniDepartment of Experimental Medicine and Surgery, Tor Vergata University Hospital, Tor Vergata University, Rome, Italy.
Emilio PiccioneAcademic Department of Surgical Sciences, Section of Gynecology, Tor Vergata University Hospital, University of Rome "Tor Vergata", 00133, Rome, Italy.
Adalgisa PietropolliAcademic Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe direct role of antiphospholipid antibodies (aPL) at maternal-fetal interface has not been fully investigated, especially whether they are involved in physiological and pathological implantation conditions, in an antiphospholipid syndrome (APS)-independent manner. In fact, trophoblast cells and placental endothelial cells at the implantation site express potential aPL targeted-phospholipid antigens (PL Ags); thus, the local production and presence of their specific antibodies, not related to APS (characterized by aPL presence in the peripheral blood), could be a potential marker of aberrant invasion, implantation and fetal-maternal immune tolerance processes.

methodsAnti-Beta

resultsaCL and anti-β

conclusionsThe presence of aPL in the AF (not related to APS) could reveal a potential clinical significance at maternal-fetal interface in selected pregnancy complications, in which an aberrant implantation process, and in turn an impaired fetal-maternal immune tolerance cross-talk, could occur.

Indexed as

AdultAmniotic FluidAntibodies, AnticardiolipinAntibodies, AntiphospholipidAntiphospholipid Syndromebeta 2-Glycoprotein IEmbryo ImplantationEndothelial CellsFemaleHumansImmune ToleranceMaternal-Fetal RelationsPlacentaPregnancyTrophoblastsAntibodies, AnticardiolipinAntibodies, Antiphospholipidbeta 2-Glycoprotein IAmniotic fluidAntiphospholipid antibodiesImpaired implantationPregnancy complications

Identifiers

PMID31615575
PMCPMC6794730
OpenAlexW2981266389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.